Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

Patients with FDA-defined Valvulopathy Permitted to Enroll in 2nd and 3rd

Pivotal Trials - Echocardiogram Screening Requirement Eliminated

SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obese patients. Known as BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), these one-year, double-blind, randomized and placebo-controlled trials are expected to collectively enroll approximately 3,750 overweight and obese patients. Consistent with Arena's proposal, the Food and Drug Administration, or FDA, is allowing patients with FDA-defined valvulopathy to enroll in both BLOSSOM and BLOOM-DM. This is different from the design of the initial lorcaserin pivotal study known as BLOOM, in which echocardiography was used to screen for patients with FDA-defined valvulopathy and exclude those patients from enrolling in the trial. Instead, in BLOSSOM and BLOOM-DM, there are no such echocardiographically defined exclusion criteria, although serial echocardiograms will be obtained to extend the lorcaserin safety database. BLOOM, BLOSSOM and BLOOM-DM comprise the entire planned pivotal trial program for lorcaserin.

"Eliminating the requirement of screening echoes, and receiving permission from the FDA to expand the patient population of the lorcaserin pivotal trial program to include patients with FDA-defined valvulopathy, is a signifi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that it ... exchange for 6,634 shares of CTI,s Series A, B ... interest of all,series of CTI,s Convertible Preferred Stock. Each ... 7,143 shares of CTI,s common stock, at a,conversion price ...
... $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo BioSciences, Inc. (Nasdaq: ... year 2008 financial results and accomplishments and provided an outlook ... Sangamo reported a consolidated net loss of $2.6 million, or ... million, or $0.17 per share, for the same period in ...
... Specialty Pharmacy is,pleased to announce two new "Navigator" ... DSP launched both a Hemophilia and IVIG,Navigator Program. ... as National,Sales Manager for both programs. Reed is ... over 18 years of pharmaceutical sales experience. Most ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... brain that controls insulin responses has been shown to ... evidence that the disease can be treated in its ... Rhode Island Hospital and Brown Medical School. , ... prevent several components of neurodegeneration and preserve learning and ...
... known that animals use song as a way of attracting ... unusual way of scaring off predators ?by singing to them. ... that wild gibbons in Thailand have developed a unique song ... survival, the gibbons appear to use the song not just ...
... 21 September, 2006 - Elsevier is delighted to ... the journal Vaccine: HPV Vaccines and Screening in ... provides a comprehensive and invaluable update for paediatricians, ... major donor institutions worldwide. , With the arrival ...
Cached Biology News:Insulin receptor stops progression of Alzheimer's disease 2Insulin receptor stops progression of Alzheimer's disease 3Singing for survival 2Singing for survival 3
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... and 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, ... with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: